Novo Nordisk A/SNVONYSE
Loading
Revenue Growth AcceleratingAccelerating
Percentile Rank62
3Y CAGR-5.9%
5Y CAGR+3.3%
Year-over-Year Change
Year-over-year revenue growth rate
3Y CAGR
-5.9%/yr
vs +81.3%/yr prior
5Y CAGR
+3.3%/yr
Recent deceleration
Acceleration
-87.2pp
Decelerating
Percentile
P62
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.61% |
| Q3 2025 | -2.45% |
| Q2 2025 | -1.58% |
| Q1 2025 | -8.87% |
| Q4 2024 | 20.15% |
| Q3 2024 | 4.78% |
| Q2 2024 | 4.15% |
| Q1 2024 | -0.78% |
| Q4 2023 | 12.14% |
| Q3 2023 | 8.16% |
| Q2 2023 | 1.75% |
| Q1 2023 | 10.97% |
| Q4 2022 | 5.54% |
| Q3 2022 | 10.42% |
| Q2 2022 | -1.82% |
| Q1 2022 | 9.65% |
| Q4 2021 | 7.61% |
| Q3 2021 | 7.81% |
| Q2 2021 | -2.26% |
| Q1 2021 | 5.18% |
| Q4 2020 | 3.92% |
| Q3 2020 | 3.07% |
| Q2 2020 | -11.42% |
| Q1 2020 | 4.50% |
| Q4 2019 | 7.07% |
| Q3 2019 | 0.80% |
| Q2 2019 | 2.54% |
| Q1 2019 | -1.48% |
| Q4 2018 | 7.10% |
| Q3 2018 | 1.30% |
| Q2 2018 | 1.77% |
| Q1 2018 | -3.79% |
| Q4 2017 | 5.18% |
| Q3 2017 | -7.07% |
| Q2 2017 | 0.65% |
| Q1 2017 | -3.79% |
| Q4 2016 | 7.39% |
| Q3 2016 | 0.28% |
| Q2 2016 | 0.91% |
| Q1 2016 | -5.76% |